Home » CuraGen, Gemini in Target Discovery Collaboration

CuraGen, Gemini in Target Discovery Collaboration

Apr 07, 2000
Premium

C

AMBRIDGE, UK--Gemini Genomics, formerly Gemini Holdings, announced that it has entered into a two-year drug target identification collaboration with CuraGen to accelerate drug discovery. CuraGen and Gemini scientists will work together to associate CuraGen's thousands of single-nucleotide polymorphisms with disease traits derived from Gemini's database of clinical populations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Halt Under Consideration

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

How's It Going to Go Over?

The Associated Press reports that gene-edited food may soon be for sale.

Meetings on Fetal Research

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

This Week in Cell

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.

What's Popular?

In Informatics

  1. Hospitals Lagging in Using Discrete Genomics Data for Clinical Decision Support

    Premium

  2. Nashville Biosciences Partners With BC Platforms to Offer Biobank Summary Data to Researchers

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.